Matteo Benelli

Prof. Dr. Matteo Benelli


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
IMIlenia Migliaccio
Ilenia Migliaccio
MBMartina Bonechi
Martina Bonechi
DRDario Romagnoli
Dario Romagnoli
GBGiulia Boccalini
Giulia Boccalini
FGFrancesca Galardi
Francesca Galardi
MBMatteo Benelli
Matteo Benelli
Cyclin dependent kinases 4 and 6 inhibitors have brought great improvements in the treatment of luminal breast cancer, but resistance is a major clinical hurdle. Multiple biomarkers of resistance have been proposed, but none is currently utilized in clinical practice. By performing single-cell RNA sequencing of seven palbociclib-naïve luminal breast cancer cell lines and palbociclib-resistant derivatives, we show that established biomarkers and pathways related to CDK4/6i resistance present marked intra- and inter- cell-line heterogeneity. Transcriptional features of resistance could be already observed in naïve cells correlating with levels of sensitivity (IC50) to palbociclib. Resistant derivatives showed transcriptional clusters that significantly varied for proliferative, estrogen response signatures or MYC targets. This marked heterogeneity was validated in the FELINE trial where, compared to the sensitive ones, ribociclib-resistant tumors developed higher clonal diversity at genetic level and showed greater trascriptional variability for genes associated with resistance. A potential signature of resistance inferred from the cell-line models, positively enriched for MYC targets and negatively enriched for estrogen response markers, was probed on the FELINE trial, separating sensitive from resistant tumors and revealing higher heterogeneity in resistant versus sensitive cells. These data suggest that heterogeneity for CDK4/6 inhibitors resistant markers might facilitate the development of resistance and challenge the validation of clinical biomarkers.

3 February 2026 in Genome Medicine
Verified
Journal Article
Open access
PDF file
MPMarta Paoli
Marta Paoli
FGFrancesca Galardi
Francesca Galardi
ANAgostina Nardone
Agostina Nardone
CBChiara Biagioni
Chiara Biagioni
DRDario Romagnoli
Dario Romagnoli
MBMatteo Benelli
Matteo Benelli
Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissu

24 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
GLGiulia Lori
Giulia Lori
CMCaterina Mancini
Caterina Mancini
CPCaterina Paffetti
Caterina Paffetti
DDDayana Desideri
Dayana Desideri
EPErica Pranzini
Erica Pranzini
Maria Letizia TaddeiMaria Letizia Taddei
Maria Letizia Taddei
Cancer progression is influenced by the dynamic interplay between tumor cells and the surrounding stromal microenvironment. Therapy-induced senescence (TIS) of stromal fibroblasts represents a common outcome of anticancer treatments, contributing to tumor progression through the senescence-associated secretory phenotype (SASP). While SASP cytokines promote cancer malignancy, the contribution of secreted metabolites from senescent cells remains poorly understood. Here, we investigate the role of senescent stromal metabolism in regulating prostate and ovarian cancer cell invasion. Conditioned media (CM) from TIS-induced human prostate (HPFs) and ovarian fibroblasts (HOFs) promote enhanced invasion of cancer cells. Invasion is partially preserved after exposure to boiled CM, suggesting a role for heat-stable metabolic factors. Metabolomic profiling of senescent fibroblasts-derived CM reveals a significant increase in Glutamine (Gln) levels, identifying senescent stromal fibroblasts as a previously unrecognized source of extracellular Gln in the tumor microenvironment (TME). Exposure of cancer cells to senescent CM increases Gln uptake, together with upregulation of the transporter SLC1A5 and increased intracellular Gln. This metabolic adaptation is associated with increased malignant phenotype including epithelial-to-mesenchymal transition (EMT) and stemness features. Extracellular Gln depletion, pharmacological inhibition of glutaminase-1 (GLS1) in cancer cells, or Gln synthetase (GS) silencing in fibroblasts markedly impair senescent fibroblasts CM-induced invasion, EMT markers expression, and stemness features in cancer cells. Stromal-derived Gln is associated with increased cancer cell invasion through activation of a redox-dependent NRF2/ETS1 signaling axis. Analysis of patient-derived transcriptomic datasets further suggests chemotherapy-associated upregulation of Gln metabolism and ETS1 expression. These findings identify senescent stromal-derived Gln as a key metabolic driver of prostate and ovarian cancer aggressiveness and reveal a TIS-associated metabolic vulnerability that could be explored in future preclinical studies.

11 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMarta Paoli
Marta Paoli
FGFrancesca Galardi
Francesca Galardi
ANAgostina Nardone
Agostina Nardone
CBChiara Biagioni
Chiara Biagioni
DRDario Romagnoli
Dario Romagnoli
MBMatteo Benelli
Matteo Benelli
The analysis of circulating tumor DNA (ctDNA) is increasingly used for monitoring disease in patients with metastatic cancer. Here, we introduce a robust and reproducible strategy combining low-pass whole methylome sequencing of plasma DNA with METER, a novel computational tool. Engaging prediction models trained on independent available datasets, METER enables the detection and quantification of tumor content (TC) and performs molecular cancer subtyping. Applied to plasma methylomes from early metastatic breast cancer patients, our method demonstrated reliable quantification, sensitive tumor detection below 3% of TC, and the ability to perform accurate Estrogen Receptor (ER) subtyping. METER provided clinically relevant predictions, underscored by associations with relevant prognostic factors, robust correlation with matched circulating tumor cells, and highly correlated with patients’ outcomes in challenging scenarios as TC<3%. Our strategy provides comprehensive and sensitive analysis of plasma samples, serving as a valuable yet cost-effective precision oncology tool.

Verified
Journal Article
Open access
PDF file
DCDiletta Cozzi
Diletta Cozzi
AGAlessio Gnerucci
Alessio Gnerucci
GZGIULIA ZANTONELLI
GIULIA ZANTONELLI
MBMatteo Benelli
Matteo Benelli
MBMaurizio Bartolucci
Maurizio Bartolucci
Background: Pulmonary embolism (PE) is a life-threatening condition in which early diagnosis and prompt treatment are essential to reduce morbidity and mortality. Recent advances in radiomics have introduced software tools for PE detection on CT pulmonary angiography (CTPA), but their application to non-contrast chest CT remains unexplored. Methods: We retrospectively identified 57 CTPA examinations performed between January 2020 and March 2023. Patients were randomly assigned to training and validation cohorts; an additional 14 PE-negative patients were included in the validation cohort. Spherical regions of interest (ROIs) were manually placed within emboli and within normal-flow pulmonary arteries. From each ROI, 836 radiomic features were extracted. Statistically significant features were identified using the Wilcoxon test. A logistic regression classifier was then developed to discriminate between embolus and control ROIs based on their radiomic signatures. Results: Of the 836 features, 242 (all derived from wavelet-filtered images) showed significant differences between embolus and normal-flow ROIs on unenhanced CT. The classifier demonstrated high diagnostic performance in the validation cohort, with an AUC of 0.87 (95% CI: 0.86–0.88) and an accuracy of 0.77 (95% CI: 0.76–0.79), with only a limited number of misclassified ROIs. Conclusions: This preliminary study demonstrates the potential of radiomics to identify thrombi on unenhanced chest CT scans, offering a promising avenue for the early detection of acute PE. The proposed model showed satisfactory diagnostic accuracy with low few misclassifications, supporting further validation in larger cohorts.

3 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GLGiulia Lori
Giulia Lori
CMCaterina Mancini
Caterina Mancini
CPCaterina Paffetti
Caterina Paffetti
DDDayana Desideri
Dayana Desideri
EPErica Pranzini
Erica Pranzini
Maria Letizia TaddeiMaria Letizia Taddei
Maria Letizia Taddei
Cancer progression is influenced by the dynamic interplay between tumor cells and the surrounding stromal microenvironment. Therapy-induced senescence (TIS) of stromal fibroblasts represents a common outcome of anticancer treatments, contributing to tumor progression through the senescence-associated secretory phenotype (SASP). While SASP cytokines promote cancer malignancy, the contribution of secreted metabolites from senescent cells remains poorly understood. Here, we investigate the role of senescent stromal metabolism in regulating prostate and ovarian cancer cell invasion. Conditioned media (CM) from TIS-induced human prostate (HPFs) and ovarian fibroblasts (HOFs) promote enhanced invasion of cancer cells. Invasion is partially preserved after exposure to boiled, protein depleted CM, suggesting a role for heat-stable metabolic factors. Metabolomic profiling of senescent fibroblasts-derived CM reveals a significant increase in Glutamine (Gln) levels. Exposure of cancer cells to senescent CM increases Gln uptake, together with upregulation of the transporter SLC1A5 and increased intracellular Gln. This metabolic adaptation is associated with increased malignant phenotype including epithelial-to-mesenchymal transition (EMT) and stemness features. Extracellular Gln depletion, pharmacological inhibition of glutaminase-1 (GLS1) in cancer cells or Gln synthetase (GS) silencing in fibroblasts markedly impair senescent fibroblasts CM-induced invasion, EMT markers expression, and stemness features in cancer cells. Mechanistically, stromal-derived Gln promotes cancer cell invasion through activation of a redox-dependent NRF2/ETS1 signaling axis. Analysis of patient-derived transcriptomic datasets further supports chemotherapy-associated upregulation of Gln metabolism and ETS1 expression. These findings identify senescent stromal-derived Gln as a key metabolic driver of prostate and ovarian cancer aggressiveness, and a potential therapeutic vulnerability in the context of TIS.